Norway-based krill harvester and processor Aker BioMarine is acquiring all krill related patents, pre-clinical and clinical data and processing equipment from Nasdaq-listed Acasti Pharma.

The transaction is a settlement towards a contractual obligation of $3.1 million (€2.9 million) Acasti has towards Aker BioMarine, and has no cash effects, said the company.

This company has over $100 million of German chicken money to spare, and it wants to invest it in aquaculture
 Read more

With this transaction Aker BioMarine will continue to consolidate all relevant krill intellectual properties.